FORMAT Study : Use of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusion - evaluation by rotem viscoelastometry (pilot single-center study).

This study is called the FORMAT study, and it's looking into better ways to help people with blood cancer who are bleeding. People with blood cancer often have problems with their blood not clotting properly, especially after strong chemotherapy treatments. This happens because chemotherapy can lower the number of 'platelets,' which are tiny blood cells essential for stopping bleeding. When patients bleed, doctors often give them platelet transfusions, but sometimes these don't work as well as hoped.

This study is testing a specific medicine called fibrinogen, which is a protein naturally found in your blood that's crucial for forming strong blood clots. Researchers want to see if giving fibrinogen alongside platelet transfusions can make the blood clot more effectively in patients where standard transfusions haven't been enough. They will use a special test that shows how quickly and strongly blood clots form, measuring this before and after giving the treatments.

The main aim is to find out if this combined approach can improve blood clotting and ultimately reduce serious bleeding in these patients. It's a 'pilot' study, which means it's a smaller, early-stage study to see if this approach is promising enough to be studied in more detail later on. This could potentially lead to better ways to manage bleeding complications for people with blood cancer.